PT1556026E - Novas formulações farmacêuticas de modafinil - Google Patents

Novas formulações farmacêuticas de modafinil Download PDF

Info

Publication number: PT1556026E
Authority: PT; Portugal
Prior art keywords: composition; modafinil; starch; weight; magnesium stearate
Prior art date: 2002-09-13

Application number

PT03752264T

Other languages

English (en)

Portuguese (pt)

Inventor

Alpa Parikh

Vincent Corvari

George Grandolfi

Original Assignee

Cephalon Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-09-13

Filing date

2003-09-11

Publication date

2009-07-23

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=31991673&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT1556026(E) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2003-09-11 Application filed by Cephalon Inc filed Critical Cephalon Inc

2009-07-23 Publication of PT1556026E publication Critical patent/PT1556026E/pt

Links

YFGHCGITMMYXAQ-UHFFFAOYSA-N 2-[(diphenylmethyl)sulfinyl]acetamide Chemical compound C=1C=CC=CC=1C(S(=O)CC(=O)N)C1=CC=CC=C1 YFGHCGITMMYXAQ-UHFFFAOYSA-N 0.000 title claims description 80
229960001165 modafinil Drugs 0.000 title claims description 70
239000008194 pharmaceutical composition Substances 0.000 title description 2
239000000203 mixture Substances 0.000 claims description 124
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 40
229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 23
235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 23
235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 claims description 21
239000003085 diluting agent Substances 0.000 claims description 21
239000000314 lubricant Substances 0.000 claims description 21
WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 claims description 20
229960001021 lactose monohydrate Drugs 0.000 claims description 19
-1 Lactose NF Monohydrate Chemical class 0.000 claims description 18
229920002472 Starch Polymers 0.000 claims description 18
235000019698 starch Nutrition 0.000 claims description 18
229920002785 Croscarmellose sodium Polymers 0.000 claims description 17
229920000881 Modified starch Polymers 0.000 claims description 17
239000011230 binding agent Substances 0.000 claims description 17
238000011282 treatment Methods 0.000 claims description 16
229920000168 Microcrystalline cellulose Polymers 0.000 claims description 15
235000019359 magnesium stearate Nutrition 0.000 claims description 15
229940016286 microcrystalline cellulose Drugs 0.000 claims description 15
235000019813 microcrystalline cellulose Nutrition 0.000 claims description 15
239000008108 microcrystalline cellulose Substances 0.000 claims description 15
238000002360 preparation method Methods 0.000 claims description 15
239000008107 starch Substances 0.000 claims description 14
239000001267 polyvinylpyrrolidone Substances 0.000 claims description 13
FSBVERYRVPGNGG-UHFFFAOYSA-N dimagnesium dioxido-bis[[oxido(oxo)silyl]oxy]silane hydrate Chemical compound O.[Mg+2].[Mg+2].[O-][Si](=O)O[Si]([O-])([O-])O[Si]([O-])=O FSBVERYRVPGNGG-UHFFFAOYSA-N 0.000 claims description 12
239000007884 disintegrant Substances 0.000 claims description 12
239000000391 magnesium silicate Substances 0.000 claims description 12
235000019792 magnesium silicate Nutrition 0.000 claims description 11
229910052919 magnesium silicate Inorganic materials 0.000 claims description 11
WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical group C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims description 10
239000001767 crosslinked sodium carboxy methyl cellulose Substances 0.000 claims description 10
229940069328 povidone Drugs 0.000 claims description 10
239000000454 talc Substances 0.000 claims description 10
229910052623 talc Inorganic materials 0.000 claims description 10
DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical group [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 9
235000012222 talc Nutrition 0.000 claims description 9
150000003839 salts Chemical class 0.000 claims description 8
229960001681 croscarmellose sodium Drugs 0.000 claims description 7
229920003082 Povidone K 90 Polymers 0.000 claims description 5
229920002261 Corn starch Polymers 0.000 claims description 4
206010062519 Poor quality sleep Diseases 0.000 claims description 4
239000008120 corn starch Substances 0.000 claims description 4
239000003814 drug Substances 0.000 claims description 4
229910052500 inorganic mineral Inorganic materials 0.000 claims description 4
239000011707 mineral Substances 0.000 claims description 4
201000002859 sleep apnea Diseases 0.000 claims description 4
208000030814 Eating disease Diseases 0.000 claims description 3
208000019454 Feeding and Eating disease Diseases 0.000 claims description 3
208000018737 Parkinson disease Diseases 0.000 claims description 3
206010041349 Somnolence Diseases 0.000 claims description 3
235000014632 disordered eating Nutrition 0.000 claims description 3
235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 3
239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 3
229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 3
UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims description 3
230000006872 improvement Effects 0.000 claims description 3
150000004760 silicates Chemical class 0.000 claims description 3
159000000000 sodium salts Chemical class 0.000 claims description 3
230000004584 weight gain Effects 0.000 claims description 3
235000019786 weight gain Nutrition 0.000 claims description 3
208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims description 2
208000036864 Attention deficit/hyperactivity disease Diseases 0.000 claims description 2
201000006474 Brain Ischemia Diseases 0.000 claims description 2
206010008120 Cerebral ischaemia Diseases 0.000 claims description 2
208000006011 Stroke Diseases 0.000 claims description 2
206010008118 cerebral infarction Diseases 0.000 claims description 2
208000010877 cognitive disease Diseases 0.000 claims description 2
CXHHBNMLPJOKQD-UHFFFAOYSA-N methyl hydrogen carbonate Chemical compound COC(O)=O CXHHBNMLPJOKQD-UHFFFAOYSA-N 0.000 claims description 2
230000007943 positive regulation of appetite Effects 0.000 claims description 2
208000015802 attention deficit-hyperactivity disease Diseases 0.000 claims 1
206010016256 fatigue Diseases 0.000 claims 1
230000000638 stimulation Effects 0.000 claims 1
239000003826 tablet Substances 0.000 description 40
239000000546 pharmaceutical excipient Substances 0.000 description 20
239000002775 capsule Substances 0.000 description 16
238000000034 method Methods 0.000 description 16
238000002156 mixing Methods 0.000 description 15
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 13
238000005550 wet granulation Methods 0.000 description 13
238000001035 drying Methods 0.000 description 12
239000007909 solid dosage form Substances 0.000 description 12
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 12
230000008569 process Effects 0.000 description 10
229940032147 starch Drugs 0.000 description 10
238000009472 formulation Methods 0.000 description 9
201000010099 disease Diseases 0.000 description 8
238000007908 dry granulation Methods 0.000 description 8
229940033134 talc Drugs 0.000 description 8
238000007906 compression Methods 0.000 description 7
230000006835 compression Effects 0.000 description 7
239000008187 granular material Substances 0.000 description 7
238000005469 granulation Methods 0.000 description 7
230000003179 granulation Effects 0.000 description 7
239000000843 powder Substances 0.000 description 7
229940117394 provigil Drugs 0.000 description 7
239000000080 wetting agent Substances 0.000 description 7
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 6
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 5
239000003795 chemical substances by application Substances 0.000 description 5
208000035475 disorder Diseases 0.000 description 5
238000004090 dissolution Methods 0.000 description 5
239000002245 particle Substances 0.000 description 5
XKJMBINCVNINCA-UHFFFAOYSA-N Alfalone Chemical compound CON(C)C(=O)NC1=CC=C(Cl)C(Cl)=C1 XKJMBINCVNINCA-UHFFFAOYSA-N 0.000 description 4
230000008901 benefit Effects 0.000 description 4
239000012530 fluid Substances 0.000 description 4
239000004615 ingredient Substances 0.000 description 4
239000008101 lactose Substances 0.000 description 4
229960001375 lactose Drugs 0.000 description 4
235000019426 modified starch Nutrition 0.000 description 4
201000003631 narcolepsy Diseases 0.000 description 4
239000006187 pill Substances 0.000 description 4
239000008213 purified water Substances 0.000 description 4
239000007787 solid Substances 0.000 description 4
241001465754 Metazoa Species 0.000 description 3
239000004480 active ingredient Substances 0.000 description 3
239000002552 dosage form Substances 0.000 description 3
230000000694 effects Effects 0.000 description 3
230000006870 function Effects 0.000 description 3
239000007903 gelatin capsule Substances 0.000 description 3
239000000463 material Substances 0.000 description 3
229920001223 polyethylene glycol Polymers 0.000 description 3
229940068917 polyethylene glycols Drugs 0.000 description 3
208000024891 symptom Diseases 0.000 description 3
229920003084 Avicel® PH-102 Polymers 0.000 description 2
GUBGYTABKSRVRQ-DCSYEGIMSA-N Beta-Lactose Chemical compound OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-DCSYEGIMSA-N 0.000 description 2
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
241000282412 Homo Species 0.000 description 2
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
229910000831 Steel Inorganic materials 0.000 description 2
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
240000008042 Zea mays Species 0.000 description 2
235000002017 Zea mays subsp mays Nutrition 0.000 description 2
239000002253 acid Substances 0.000 description 2
239000008186 active pharmaceutical agent Substances 0.000 description 2
CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 2
239000008116 calcium stearate Substances 0.000 description 2
235000013539 calcium stearate Nutrition 0.000 description 2
OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
239000001768 carboxy methyl cellulose Substances 0.000 description 2
235000010980 cellulose Nutrition 0.000 description 2
229920002678 cellulose Polymers 0.000 description 2
239000001913 cellulose Substances 0.000 description 2
150000001875 compounds Chemical class 0.000 description 2
239000007891 compressed tablet Substances 0.000 description 2
238000009826 distribution Methods 0.000 description 2
229940079593 drug Drugs 0.000 description 2
238000007580 dry-mixing Methods 0.000 description 2
239000013020 final formulation Substances 0.000 description 2
239000000796 flavoring agent Substances 0.000 description 2
229920000159 gelatin Polymers 0.000 description 2
235000019322 gelatine Nutrition 0.000 description 2
230000005484 gravity Effects 0.000 description 2
238000000227 grinding Methods 0.000 description 2
208000013403 hyperactivity Diseases 0.000 description 2
239000011159 matrix material Substances 0.000 description 2
238000003801 milling Methods 0.000 description 2
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical class CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
239000003960 organic solvent Substances 0.000 description 2
239000000651 prodrug Substances 0.000 description 2
229940002612 prodrug Drugs 0.000 description 2
235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
229920001027 sodium carboxymethylcellulose Polymers 0.000 description 2
229920003109 sodium starch glycolate Polymers 0.000 description 2
239000008109 sodium starch glycolate Substances 0.000 description 2
229940079832 sodium starch glycolate Drugs 0.000 description 2
239000000243 solution Substances 0.000 description 2
239000010959 steel Substances 0.000 description 2
239000007916 tablet composition Substances 0.000 description 2
230000001225 therapeutic effect Effects 0.000 description 2
229930195727 α-lactose Natural products 0.000 description 2
229930195724 β-lactose Natural products 0.000 description 2
DNXIKVLOVZVMQF-UHFFFAOYSA-N (3beta,16beta,17alpha,18beta,20alpha)-17-hydroxy-11-methoxy-18-[(3,4,5-trimethoxybenzoyl)oxy]-yohimban-16-carboxylic acid, methyl ester Natural products C1C2CN3CCC(C4=CC=C(OC)C=C4N4)=C4C3CC2C(C(=O)OC)C(O)C1OC(=O)C1=CC(OC)=C(OC)C(OC)=C1 DNXIKVLOVZVMQF-UHFFFAOYSA-N 0.000 description 1
KWTSXDURSIMDCE-QMMMGPOBSA-N (S)-amphetamine Chemical compound C[C@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-QMMMGPOBSA-N 0.000 description 1
IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
LDCYZAJDBXYCGN-VIFPVBQESA-N 5-hydroxy-L-tryptophan Chemical compound C1=C(O)C=C2C(C[C@H](N)C(O)=O)=CNC2=C1 LDCYZAJDBXYCGN-VIFPVBQESA-N 0.000 description 1
229940000681 5-hydroxytryptophan Drugs 0.000 description 1
229910002012 Aerosil® Inorganic materials 0.000 description 1
208000024827 Alzheimer disease Diseases 0.000 description 1
QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
208000000044 Amnesia Diseases 0.000 description 1
241000416162 Astragalus gummifer Species 0.000 description 1
241000282465 Canis Species 0.000 description 1
241000282472 Canis lupus familiaris Species 0.000 description 1
244000303965 Cyamopsis psoralioides Species 0.000 description 1
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
206010012289 Dementia Diseases 0.000 description 1
208000007590 Disorders of Excessive Somnolence Diseases 0.000 description 1
LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
208000034347 Faecal incontinence Diseases 0.000 description 1
241000282326 Felis catus Species 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
239000001828 Gelatine Substances 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
240000007472 Leucaena leucocephala Species 0.000 description 1
235000010643 Leucaena leucocephala Nutrition 0.000 description 1
241000124008 Mammalia Species 0.000 description 1
229930195725 Mannitol Natural products 0.000 description 1
208000026139 Memory disease Diseases 0.000 description 1
229940123685 Monoamine oxidase inhibitor Drugs 0.000 description 1
240000007594 Oryza sativa Species 0.000 description 1
235000007164 Oryza sativa Nutrition 0.000 description 1
RSDOPYMFZBJHRL-UHFFFAOYSA-N Oxotremorine Chemical compound O=C1CCCN1CC#CCN1CCCC1 RSDOPYMFZBJHRL-UHFFFAOYSA-N 0.000 description 1
239000008118 PEG 6000 Substances 0.000 description 1
229920001030 Polyethylene Glycol 4000 Polymers 0.000 description 1
229920002584 Polyethylene Glycol 6000 Polymers 0.000 description 1
241000700159 Rattus Species 0.000 description 1
LCQMZZCPPSWADO-UHFFFAOYSA-N Reserpilin Natural products COC(=O)C1COCC2CN3CCc4c([nH]c5cc(OC)c(OC)cc45)C3CC12 LCQMZZCPPSWADO-UHFFFAOYSA-N 0.000 description 1
QEVHRUUCFGRFIF-SFWBKIHZSA-N Reserpine Natural products O=C(OC)[C@@H]1[C@H](OC)[C@H](OC(=O)c2cc(OC)c(OC)c(OC)c2)C[C@H]2[C@@H]1C[C@H]1N(C2)CCc2c3c([nH]c12)cc(OC)cc3 QEVHRUUCFGRFIF-SFWBKIHZSA-N 0.000 description 1
208000032140 Sleepiness Diseases 0.000 description 1
VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
BCKXLBQYZLBQEK-KVVVOXFISA-M Sodium oleate Chemical compound [Na+].CCCCCCCC\C=C/CCCCCCCC([O-])=O BCKXLBQYZLBQEK-KVVVOXFISA-M 0.000 description 1
244000061456 Solanum tuberosum Species 0.000 description 1
235000002595 Solanum tuberosum Nutrition 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
229920001615 Tragacanth Polymers 0.000 description 1
235000021307 Triticum Nutrition 0.000 description 1
244000098338 Triticum aestivum Species 0.000 description 1
206010046543 Urinary incontinence Diseases 0.000 description 1
TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
BLGXFZZNTVWLAY-CCZXDCJGSA-N Yohimbine Natural products C1=CC=C2C(CCN3C[C@@H]4CC[C@@H](O)[C@H]([C@H]4C[C@H]33)C(=O)OC)=C3NC2=C1 BLGXFZZNTVWLAY-CCZXDCJGSA-N 0.000 description 1
235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
235000016383 Zea mays subsp huehuetenangensis Nutrition 0.000 description 1
150000003869 acetamides Chemical class 0.000 description 1
239000013543 active substance Substances 0.000 description 1
230000002730 additional effect Effects 0.000 description 1
239000003463 adsorbent Substances 0.000 description 1
230000002411 adverse Effects 0.000 description 1
229910052783 alkali metal Inorganic materials 0.000 description 1
208000026935 allergic disease Diseases 0.000 description 1
229910052782 aluminium Inorganic materials 0.000 description 1
XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
229940025084 amphetamine Drugs 0.000 description 1
230000000181 anti-adherent effect Effects 0.000 description 1
239000003911 antiadherent Substances 0.000 description 1
VMWNQDUVQKEIOC-CYBMUJFWSA-N apomorphine Chemical compound C([C@H]1N(C)CC2)C3=CC=C(O)C(O)=C3C3=C1C2=CC=C3 VMWNQDUVQKEIOC-CYBMUJFWSA-N 0.000 description 1
229960004046 apomorphine Drugs 0.000 description 1
230000036528 appetite Effects 0.000 description 1
235000019789 appetite Nutrition 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
230000003542 behavioural effect Effects 0.000 description 1
BLGXFZZNTVWLAY-UHFFFAOYSA-N beta-Yohimbin Natural products C1=CC=C2C(CCN3CC4CCC(O)C(C4CC33)C(=O)OC)=C3NC2=C1 BLGXFZZNTVWLAY-UHFFFAOYSA-N 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
230000000903 blocking effect Effects 0.000 description 1
235000010410 calcium alginate Nutrition 0.000 description 1
239000000648 calcium alginate Substances 0.000 description 1
229960002681 calcium alginate Drugs 0.000 description 1
FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
239000000378 calcium silicate Substances 0.000 description 1
229910052918 calcium silicate Inorganic materials 0.000 description 1
PASHVRUKOFIRIK-UHFFFAOYSA-L calcium sulfate dihydrate Chemical compound O.O.[Ca+2].[O-]S([O-])(=O)=O PASHVRUKOFIRIK-UHFFFAOYSA-L 0.000 description 1
OKHHGHGGPDJQHR-YMOPUZKJSA-L calcium;(2s,3s,4s,5s,6r)-6-[(2r,3s,4r,5s,6r)-2-carboxy-6-[(2r,3s,4r,5s,6r)-2-carboxylato-4,5,6-trihydroxyoxan-3-yl]oxy-4,5-dihydroxyoxan-3-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylate Chemical compound [Ca+2].O[C@@H]1[C@H](O)[C@H](O)O[C@@H](C([O-])=O)[C@H]1O[C@H]1[C@@H](O)[C@@H](O)[C@H](O[C@H]2[C@H]([C@@H](O)[C@H](O)[C@H](O2)C([O-])=O)O)[C@H](C(O)=O)O1 OKHHGHGGPDJQHR-YMOPUZKJSA-L 0.000 description 1
OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
239000007963 capsule composition Substances 0.000 description 1
125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
210000003169 central nervous system Anatomy 0.000 description 1
230000002490 cerebral effect Effects 0.000 description 1
238000002144 chemical decomposition reaction Methods 0.000 description 1
238000004140 cleaning Methods 0.000 description 1
229940075614 colloidal silicon dioxide Drugs 0.000 description 1
239000003086 colorant Substances 0.000 description 1
239000000039 congener Substances 0.000 description 1
238000007596 consolidation process Methods 0.000 description 1
238000010924 continuous production Methods 0.000 description 1
238000013270 controlled release Methods 0.000 description 1
235000005822 corn Nutrition 0.000 description 1
235000005687 corn oil Nutrition 0.000 description 1
239000002285 corn oil Substances 0.000 description 1
229940099112 cornstarch Drugs 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
230000007812 deficiency Effects 0.000 description 1
230000006735 deficit Effects 0.000 description 1
229940096516 dextrates Drugs 0.000 description 1
239000008121 dextrose Substances 0.000 description 1
235000019700 dicalcium phosphate Nutrition 0.000 description 1
229940095079 dicalcium phosphate anhydrous Drugs 0.000 description 1
239000008298 dragée Substances 0.000 description 1
239000011363 dried mixture Substances 0.000 description 1
230000009977 dual effect Effects 0.000 description 1
239000000975 dye Substances 0.000 description 1
239000007938 effervescent tablet Substances 0.000 description 1
230000008030 elimination Effects 0.000 description 1
238000003379 elimination reaction Methods 0.000 description 1
239000002662 enteric coated tablet Substances 0.000 description 1
MVPICKVDHDWCJQ-UHFFFAOYSA-N ethyl 3-pyrrolidin-1-ylpropanoate Chemical compound CCOC(=O)CCN1CCCC1 MVPICKVDHDWCJQ-UHFFFAOYSA-N 0.000 description 1
230000001747 exhibiting effect Effects 0.000 description 1
239000000945 filler Substances 0.000 description 1
238000011049 filling Methods 0.000 description 1
239000007941 film coated tablet Substances 0.000 description 1
235000019634 flavors Nutrition 0.000 description 1
235000013355 food flavoring agent Nutrition 0.000 description 1
235000003599 food sweetener Nutrition 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
239000007902 hard capsule Substances 0.000 description 1
239000003906 humectant Substances 0.000 description 1
235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
239000001863 hydroxypropyl cellulose Substances 0.000 description 1
239000003326 hypnotic agent Substances 0.000 description 1
230000000147 hypnotic effect Effects 0.000 description 1
230000007794 irritation Effects 0.000 description 1
208000028867 ischemia Diseases 0.000 description 1
239000002655 kraft paper Substances 0.000 description 1
238000002372 labelling Methods 0.000 description 1
238000011031 large-scale manufacturing process Methods 0.000 description 1
229960002366 magnesium silicate Drugs 0.000 description 1
229940057948 magnesium stearate Drugs 0.000 description 1
229910000386 magnesium trisilicate Inorganic materials 0.000 description 1
235000019793 magnesium trisilicate Nutrition 0.000 description 1
229940099273 magnesium trisilicate Drugs 0.000 description 1
235000009973 maize Nutrition 0.000 description 1
239000000594 mannitol Substances 0.000 description 1
235000010355 mannitol Nutrition 0.000 description 1
230000006984 memory degeneration Effects 0.000 description 1
208000023060 memory loss Diseases 0.000 description 1
HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
230000002503 metabolic effect Effects 0.000 description 1
229920000609 methyl cellulose Polymers 0.000 description 1
239000001923 methylcellulose Substances 0.000 description 1
230000005012 migration Effects 0.000 description 1
238000013508 migration Methods 0.000 description 1
230000003278 mimic effect Effects 0.000 description 1
239000002480 mineral oil Substances 0.000 description 1
229940079523 modafinil 200 mg Drugs 0.000 description 1
QARQPIWTMBRJFX-UHFFFAOYSA-N modafinil acid Chemical class C=1C=CC=CC=1C(S(=O)CC(=O)O)C1=CC=CC=C1 QARQPIWTMBRJFX-UHFFFAOYSA-N 0.000 description 1
238000012986 modification Methods 0.000 description 1
230000004048 modification Effects 0.000 description 1
239000002899 monoamine oxidase inhibitor Substances 0.000 description 1
201000006417 multiple sclerosis Diseases 0.000 description 1
229920001206 natural gum Polymers 0.000 description 1
LDCYZAJDBXYCGN-UHFFFAOYSA-N oxitriptan Natural products C1=C(O)C=C2C(CC(N)C(O)=O)=CNC2=C1 LDCYZAJDBXYCGN-UHFFFAOYSA-N 0.000 description 1
235000010987 pectin Nutrition 0.000 description 1
239000001814 pectin Substances 0.000 description 1
229920001277 pectin Polymers 0.000 description 1
239000000825 pharmaceutical preparation Substances 0.000 description 1
229940127557 pharmaceutical product Drugs 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
239000000049 pigment Substances 0.000 description 1
229920005862 polyol Polymers 0.000 description 1
150000003077 polyols Chemical class 0.000 description 1
229920002451 polyvinyl alcohol Polymers 0.000 description 1
235000019422 polyvinyl alcohol Nutrition 0.000 description 1
235000012015 potatoes Nutrition 0.000 description 1
238000011321 prophylaxis Methods 0.000 description 1
BJOIZNZVOZKDIG-MDEJGZGSSA-N reserpine Chemical compound O([C@H]1[C@@H]([C@H]([C@H]2C[C@@H]3C4=C([C]5C=CC(OC)=CC5=N4)CCN3C[C@H]2C1)C(=O)OC)OC)C(=O)C1=CC(OC)=C(OC)C(OC)=C1 BJOIZNZVOZKDIG-MDEJGZGSSA-N 0.000 description 1
229960003147 reserpine Drugs 0.000 description 1
230000029058 respiratory gaseous exchange Effects 0.000 description 1
235000009566 rice Nutrition 0.000 description 1
MDMGHDFNKNZPAU-UHFFFAOYSA-N roserpine Natural products C1C2CN3CCC(C4=CC=C(OC)C=C4N4)=C4C3CC2C(OC(C)=O)C(OC)C1OC(=O)C1=CC(OC)=C(OC)C(OC)=C1 MDMGHDFNKNZPAU-UHFFFAOYSA-N 0.000 description 1
238000012216 screening Methods 0.000 description 1
208000019116 sleep disease Diseases 0.000 description 1
230000037321 sleepiness Effects 0.000 description 1
239000001632 sodium acetate Substances 0.000 description 1
235000017281 sodium acetate Nutrition 0.000 description 1
235000010413 sodium alginate Nutrition 0.000 description 1
239000000661 sodium alginate Substances 0.000 description 1
229940005550 sodium alginate Drugs 0.000 description 1
WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
239000004299 sodium benzoate Substances 0.000 description 1
235000010234 sodium benzoate Nutrition 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
229940045902 sodium stearyl fumarate Drugs 0.000 description 1
239000002904 solvent Substances 0.000 description 1
239000000600 sorbitol Substances 0.000 description 1
239000007921 spray Substances 0.000 description 1
229910001220 stainless steel Inorganic materials 0.000 description 1
239000010935 stainless steel Substances 0.000 description 1
229940071117 starch glycolate Drugs 0.000 description 1
239000006190 sub-lingual tablet Substances 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
235000000346 sugar Nutrition 0.000 description 1
239000007940 sugar coated tablet Substances 0.000 description 1
150000008163 sugars Chemical class 0.000 description 1
150000003457 sulfones Chemical group 0.000 description 1
239000004094 surface-active agent Substances 0.000 description 1
239000003765 sweetening agent Substances 0.000 description 1
239000006188 syrup Substances 0.000 description 1
235000020357 syrup Nutrition 0.000 description 1
230000008685 targeting Effects 0.000 description 1
239000004408 titanium dioxide Substances 0.000 description 1
230000001988 toxicity Effects 0.000 description 1
231100000419 toxicity Toxicity 0.000 description 1
235000010487 tragacanth Nutrition 0.000 description 1
239000000196 tragacanth Substances 0.000 description 1
229940116362 tragacanth Drugs 0.000 description 1
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
235000019731 tricalcium phosphate Nutrition 0.000 description 1
230000002485 urinary effect Effects 0.000 description 1
235000015112 vegetable and seed oil Nutrition 0.000 description 1
239000008158 vegetable oil Substances 0.000 description 1
239000000811 xylitol Substances 0.000 description 1
HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
235000010447 xylitol Nutrition 0.000 description 1
229960002675 xylitol Drugs 0.000 description 1
229960000317 yohimbine Drugs 0.000 description 1
BLGXFZZNTVWLAY-SCYLSFHTSA-N yohimbine Chemical compound C1=CC=C2C(CCN3C[C@@H]4CC[C@H](O)[C@@H]([C@H]4C[C@H]33)C(=O)OC)=C3NC2=C1 BLGXFZZNTVWLAY-SCYLSFHTSA-N 0.000 description 1
AADVZSXPNRLYLV-UHFFFAOYSA-N yohimbine carboxylic acid Natural products C1=CC=C2C(CCN3CC4CCC(C(C4CC33)C(O)=O)O)=C3NC2=C1 AADVZSXPNRLYLV-UHFFFAOYSA-N 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Epidemiology (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Molecular Biology (AREA)
Biophysics (AREA)
Psychiatry (AREA)
Diabetes (AREA)
Psychology (AREA)
Obesity (AREA)
Hematology (AREA)
Vascular Medicine (AREA)
Child & Adolescent Psychology (AREA)
Hospice & Palliative Care (AREA)
Toxicology (AREA)
Urology & Nephrology (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Pulmonology (AREA)
Medicinal Preparation (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

PT03752264T 2002-09-13 2003-09-11 Novas formulações farmacêuticas de modafinil PT1556026E (pt)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US10/243,557 US7229644B2 (en)	2002-05-23	2002-09-13	Pharmaceutical formulations of modafinil

Publications (1)

Publication Number	Publication Date
PT1556026E true PT1556026E (pt)	2009-07-23

Family

ID=31991673

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PT03752264T PT1556026E (pt)	2002-09-13	2003-09-11	Novas formulações farmacêuticas de modafinil

Country Status (28)

Country	Link
US (1)	US7229644B2 (de)
EP (1)	EP1556026B1 (de)
JP (2)	JP5415662B2 (de)
KR (1)	KR101125361B1 (de)
CN (2)	CN101606915B (de)
AR (1)	AR041242A1 (de)
AT (1)	ATE434435T1 (de)
AU (1)	AU2003270563B2 (de)
BR (1)	BR0314515A (de)
CA (1)	CA2498506C (de)
CY (1)	CY1109465T1 (de)
DE (1)	DE60328119D1 (de)
DK (1)	DK1556026T3 (de)
EA (1)	EA008506B1 (de)
ES (1)	ES2325860T3 (de)
IL (1)	IL167187A (de)
IS (1)	IS2707B (de)
MX (1)	MXPA05002832A (de)
MY (1)	MY140081A (de)
NO (1)	NO333725B1 (de)
NZ (1)	NZ538940A (de)
PL (1)	PL375831A1 (de)
PT (1)	PT1556026E (de)
SI (1)	SI1556026T1 (de)
TW (1)	TWI316406B (de)
UA (1)	UA88867C2 (de)
WO (1)	WO2004024133A1 (de)
ZA (1)	ZA200502792B (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ES2277937T3 (es)	2000-07-27	2007-08-01	Teva Pharmaceutical Industries Ltd.	Modafinilo puro y cristalino y su procedimiento de preparacion.
US20080058424A1 (en) *	2002-05-23	2008-03-06	Cephalon, Inc.	Novel pharmaceutical formulations of modafinil
US7229644B2 (en) *	2002-05-23	2007-06-12	Cephalon, Inc.	Pharmaceutical formulations of modafinil
US20040116532A1 (en)	2002-09-13	2004-06-17	Craig Heacock	Pharmaceutical formulations of modafinil
FR2849029B1 (fr) *	2002-12-20	2005-03-18	Lafon Labor	Procede de preparation et formes cristallines des enantiomeres optiques du modafinil.
US20040253308A1 (en) *	2003-04-29	2004-12-16	Barr Laboratories, Inc.	Surface-treated modafinil particles
US8153159B2 (en) *	2003-09-18	2012-04-10	Cephalon, Inc.	Modafinil modified release pharmaceutical compositions
US7368591B2 (en)	2003-09-19	2008-05-06	Cephalon France	Process for enantioselective synthesis of single enantiomers of modafinil by asymmetric oxidation
US20050137264A1 (en) *	2003-12-22	2005-06-23	Patel Ashish A.	Modafinil compositions
US20060024370A1 (en)	2004-07-29	2006-02-02	Cephalon France	Modafinil oral lyophilizate
US8173169B2 (en) *	2007-07-11	2012-05-08	Hikma Pharmaceuticals	Formulation and process for the preparation of modafinil
EP3002005A1 (de) *	2014-09-30	2016-04-06	Molkerei Meggle Wasserburg GmbH & Co. Kg	Direktkomprimierter Hilfsstoff auf Basis von Lactose, Cellulose und Stärke
US9616068B2 (en)	2014-10-27	2017-04-11	Pohela LLC	Animal training using cognitive enhancement
FR3117775B1 (fr) *	2020-12-18	2024-04-19	Commissariat Energie Atomique	Produit pharmaceutique, son procédé de préparation et ses utilisations

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US1570994A (en) *	1923-11-20	1926-01-26	William A Cook	Spring-forming die
GB1584462A (en) *	1977-03-31	1981-02-11	Lafon Labor	N-diaryl-malonamide and diarylmethyl-sulphinyl-acetamide derivatives and pharmaceutical compositions containing them
HU187215B (en) *	1983-01-26	1985-11-28	Egyt Gyogyszervegyeszeti Gyar	Method for producing pharmaceutical product of high actor content and prolonged effect
FR2593809B1 (fr) *	1986-01-31	1988-07-22	Lafon Labor	Benzhydrylsulfinylacetamide, procede de preparation et utilisation en therapeutique
FR2663225B1 (fr) *	1990-06-14	1994-11-04	Lafon Labor	Nouvelle utilisation du modafinil.
FR2684875B1 (fr) *	1991-12-13	1995-05-24	Lafon Labor	Utilisation du modafinil pour la fabrication d'un medicament ayant un effet anti-ischemique.
FR2697162B1 (fr) *	1992-10-23	1995-01-13	Lafon Labor	Utilisation du modafinil pour la fabrication d'un médicament pour le traitement de l'incontinence urinaire et des troubles sphinctériens urétro vésicaux.
GB9225492D0 (en) *	1992-12-05	1993-01-27	Glaxo Group Ltd	Amine derivatives
FR2702968B1 (fr)	1993-03-23	1995-06-23	Lafon Labor	Procédé de préparation de particules renfermant un ingrédient actif par extrusion et lyophilisation .
US5843347A (en) *	1993-03-23	1998-12-01	Laboratoire L. Lafon	Extrusion and freeze-drying method for preparing particles containing an active ingredient
FR2706767B1 (de) *	1993-06-22	1995-09-08	Lafon Labor
US5618845A (en) *	1994-10-06	1997-04-08	Cephalon, Inc.	Acetamide derivative having defined particle size
SI9500173B (sl) *	1995-05-19	2002-02-28	Lek,	Trofazna farmacevtska oblika s konstantnim in kontroliranim sproščanjem amorfne učinkovine za enkrat dnevno aplikacijo
CA2243237C (en) *	1996-01-19	2008-09-02	Glaxo Group Limited	Use of valaciclovir for the manufacture of a medicament for the treatment of genital herpes by a single daily application
JPH09208468A (ja) *	1996-02-02	1997-08-12	Dainippon Pharmaceut Co Ltd	ｐ−クロロ−Ｎ−（２−モルホリノエチル）ベンズアミドを含有する錠剤
US5948437A (en) *	1996-05-23	1999-09-07	Zeneca Limited	Pharmaceutical compositions using thiazepine
JPH10179045A (ja) *	1996-12-25	1998-07-07	Osaka Kagaku Gokin Kk	シート状可食性成形物
CN1277550A (zh) *	1997-09-11	2000-12-20	尼科梅德丹麦有限公司	非甾体抗炎药物(NSAIDs)的改进释放的复合型组合物
FR2772615B1 (fr) *	1997-12-23	2002-06-14	Lipha	Comprime multicouche pour la liberation instantanee puis prolongee de substances actives
SI20109A (sl) *	1998-12-16	2000-06-30	LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d.	Stabilna farmacevtska formulacija
HUP0104606A3 (en) *	1998-12-18	2003-01-28	Basf Ag	A pharmaceutical mixture comprising a profen
PL356899A1 (en)	1998-12-18	2004-07-12	Abbott Laboratories	Controlled release formulation of divalproex sodium
US6267985B1 (en) *	1999-06-30	2001-07-31	Lipocine Inc.	Clear oil-containing pharmaceutical compositions
US6294192B1 (en) *	1999-02-26	2001-09-25	Lipocine, Inc.	Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
US6248363B1 (en) *	1999-11-23	2001-06-19	Lipocine, Inc.	Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US7374779B2 (en) *	1999-02-26	2008-05-20	Lipocine, Inc.	Pharmaceutical formulations and systems for improved absorption and multistage release of active agents
US20030104048A1 (en) *	1999-02-26	2003-06-05	Lipocine, Inc.	Pharmaceutical dosage forms for highly hydrophilic materials
US6346548B1 (en) *	1999-08-16	2002-02-12	Cephalon, Inc.	Compositions including modafinil for treatment of attention deficit hyperactivity disorder and multiple sclerosis fatigue
US6455588B1 (en)	1999-08-20	2002-09-24	Cephalon, Inc.	Compositions including modafinil for treatment of eating disorders and for appetite stimulation
US6204245B1 (en) *	1999-09-17	2001-03-20	The Regents Of The University Of California	Treatment of narcolepsy with immunosuppressants
JP3888064B2 (ja) *	2000-01-27	2007-02-28	田辺製薬株式会社	徐放性製剤およびその製法
US20010034373A1 (en) *	2000-02-09	2001-10-25	Matthew Miller	Low dose modafinil for enhancement of cognitive function
US6670358B2 (en) *	2000-05-16	2003-12-30	Cephalon, Inc.	Substituted thioacetamides
US6492396B2 (en) *	2000-05-16	2002-12-10	Cephalon, Inc.	Substituted thioacetamides
JP4593074B2 (ja)	2000-10-11	2010-12-08	セフアロン・インコーポレーテツド	モダフィニル化合物含有組成物
US7297346B2 (en)	2001-05-25	2007-11-20	Cephalon Inc.	Pharmaceutical formulations of modafinil
US7576133B2 (en) *	2002-03-11	2009-08-18	Carl Henry Lawyer	Methods and compositions for nasal administration of modafinil
US7229644B2 (en) *	2002-05-23	2007-06-12	Cephalon, Inc.	Pharmaceutical formulations of modafinil
US7115281B2 (en)	2002-07-08	2006-10-03	Ranbaxy Laboratories Limited	Processes for the preparation of oral dosage formulations of modafinil
EP1526842A1 (de)	2002-07-25	2005-05-04	Ranbaxy Laboratories, Ltd.	Verfahren zur herstellung oraler modafinilarzneimittel
US20040116532A1 (en) *	2002-09-13	2004-06-17	Craig Heacock	Pharmaceutical formulations of modafinil

2002
- 2002-09-13 US US10/243,557 patent/US7229644B2/en not_active Expired - Fee Related
2003
- 2003-09-08 TW TW092124721A patent/TWI316406B/zh not_active IP Right Cessation
- 2003-09-09 MY MYPI20033411A patent/MY140081A/en unknown
- 2003-09-11 NZ NZ538940A patent/NZ538940A/en not_active IP Right Cessation
- 2003-09-11 JP JP2004536511A patent/JP5415662B2/ja not_active Expired - Lifetime
- 2003-09-11 WO PCT/US2003/028528 patent/WO2004024133A1/en not_active Ceased
- 2003-09-11 UA UAA200503450A patent/UA88867C2/ru unknown
- 2003-09-11 CN CN2009101401499A patent/CN101606915B/zh not_active Expired - Fee Related
- 2003-09-11 ES ES03752264T patent/ES2325860T3/es not_active Expired - Lifetime
- 2003-09-11 KR KR1020057004186A patent/KR101125361B1/ko not_active Expired - Fee Related
- 2003-09-11 AU AU2003270563A patent/AU2003270563B2/en not_active Ceased
- 2003-09-11 BR BR0314515-8A patent/BR0314515A/pt not_active Application Discontinuation
- 2003-09-11 MX MXPA05002832A patent/MXPA05002832A/es active IP Right Grant
- 2003-09-11 EP EP03752264A patent/EP1556026B1/de not_active Expired - Lifetime
- 2003-09-11 SI SI200331620T patent/SI1556026T1/sl unknown
- 2003-09-11 CA CA2498506A patent/CA2498506C/en not_active Expired - Fee Related
- 2003-09-11 CN CNB038217481A patent/CN100528150C/zh not_active Expired - Fee Related
- 2003-09-11 EA EA200500486A patent/EA008506B1/ru not_active IP Right Cessation
- 2003-09-11 DE DE60328119T patent/DE60328119D1/de not_active Expired - Lifetime
- 2003-09-11 PT PT03752264T patent/PT1556026E/pt unknown
- 2003-09-11 DK DK03752264T patent/DK1556026T3/da active
- 2003-09-11 AT AT03752264T patent/ATE434435T1/de active
- 2003-09-11 PL PL03375831A patent/PL375831A1/xx not_active Application Discontinuation
- 2003-09-12 AR ARP030103305A patent/AR041242A1/es unknown
2005
- 2005-02-24 IS IS7715A patent/IS2707B/is unknown
- 2005-03-01 IL IL167187A patent/IL167187A/en unknown
- 2005-03-03 NO NO20051138A patent/NO333725B1/no not_active IP Right Cessation
2006
- 2006-01-17 ZA ZA200502792A patent/ZA200502792B/en unknown
2009
- 2009-09-10 CY CY20091100942T patent/CY1109465T1/el unknown
2013
- 2013-09-18 JP JP2013193257A patent/JP2014028833A/ja active Pending

Also Published As

Publication number	Publication date
JP5415662B2 (ja)	2014-02-12
ATE434435T1 (de)	2009-07-15
UA88867C2 (ru)	2009-12-10
US7229644B2 (en)	2007-06-12
TWI316406B (en)	2009-11-01
ES2325860T3 (es)	2009-09-22
CN101606915A (zh)	2009-12-23
PL375831A1 (en)	2005-12-12
ZA200502792B (en)	2006-03-29
MXPA05002832A (es)	2005-08-16
CY1109465T1 (el)	2014-08-13
EA200500486A1 (ru)	2005-08-25
CN101606915B (zh)	2012-01-11
DK1556026T3 (da)	2009-08-24
EP1556026A1 (de)	2005-07-27
EP1556026B1 (de)	2009-06-24
AR041242A1 (es)	2005-05-11
HK1078265A1 (en)	2006-03-10
JP2006501270A (ja)	2006-01-12
IS7715A (is)	2005-02-24
WO2004024133A1 (en)	2004-03-25
BR0314515A (pt)	2005-08-09
TW200500097A (en)	2005-01-01
NO333725B1 (no)	2013-09-02
IL167187A (en)	2010-12-30
DE60328119D1 (de)	2009-08-06
IS2707B (is)	2011-01-15
WO2004024133B1 (en)	2004-05-06
AU2003270563B2 (en)	2008-11-13
NZ538940A (en)	2008-07-31
CN100528150C (zh)	2009-08-19
EA008506B1 (ru)	2007-06-29
US20030220403A1 (en)	2003-11-27
AU2003270563A1 (en)	2004-04-30
MY140081A (en)	2009-11-30
KR101125361B1 (ko)	2012-03-27
JP2014028833A (ja)	2014-02-13
KR20050053648A (ko)	2005-06-08
CA2498506C (en)	2012-01-03
SI1556026T1 (sl)	2009-12-31
CN1681485A (zh)	2005-10-12
CA2498506A1 (en)	2004-03-25
NO20051138L (no)	2005-03-21

Publication	Publication Date	Title
CA2448456C (en)	2010-07-27	Solid pharmaceutical formulations comprising modafinil
AU2002318155A1 (en)	2003-05-08	Solid pharmaceutical formulations comprising modafinil
JP2014028833A (ja)	2014-02-13	モダフィニルの新規の医薬製剤
US20120010216A1 (en)	2012-01-12	Pharmaceutical compositions containing vanoxerine
US20080058424A1 (en)	2008-03-06	Novel pharmaceutical formulations of modafinil
HK1078265B (en)	2010-03-19	Novel pharmaceutical formulations of modafinil
HK1061652B (en)	2007-07-06	Solid pharmaceutical formulations comprising modafinil